One of the most robustly campaigned and well-known drugs for treating COVID is Paxlovid. Yet the drug’s limited clinical studies and numerous drug interactions raise questions of safety for COVID patients.
Approved for Emergency Use Authorization (EUA) in December 2021 and promoted by the Food and Drug Administration (FDA), health officials, and politicians alike, Paxlovid is fast becoming the one-track drug for early COVID treatment.
